Sihuan Pharmaceutical Holdings logo

460 - Sihuan Pharmaceutical Holdings Share Price

HK$0.9 0.0  0.0%

Last Trade - 3:59am

Sector
Healthcare
Size
Mid Cap
Market Cap £822.9m
Enterprise Value £315.9m
Revenue £259.0m
Position in Universe 825th / 5951
Bullish
Bearish
Unlock 460 Revenue
Momentum
Relative Strength (%)
1m -12.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -14.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
3,084 3,167 3,186 2,746 2,917 2,887 2,376 2,838 -1.3%
+29.3 -3.3 +7.8 -15.8 +20.9 +11.8
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, SihuanPharmaceutical Holdings Group Ltd revenues decreased 36% toRMB1.05B. Net income before extraordinary items totaledRMB174.4M vs. loss of RMB2B. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Net Income reflectsImpairment loss on goodwill decrease from RMB2.84B(expense) to RMB0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

460 Revenue Unlock 460 Revenue

Net Income

460 Net Income Unlock 460 Revenue

Normalised EPS

460 Normalised EPS Unlock 460 Revenue

PE Ratio Range

460 PE Ratio Range Unlock 460 Revenue

Dividend Yield Range

460 Dividend Yield Range Unlock 460 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
460 EPS Forecasts Unlock 460 Revenue
Profile Summary

Sihuan Pharmaceutical Holding Group Ltd. is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The Company is mainly engaged in the research and development, manufacture and sales of pharmaceutical products in China. Its products are applicable in cardio-cerebral vascular (CCV) system, central nervous system, metabolism, oncology and anti-infective fields. Its CCV products include Kelinao, Anjieli and Oudimei, among others. Its non-CCV products include Ren’Ao, Metronidazole and Clindamycin, among others.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated April 26, 2006
Public Since October 28, 2010
No. of Shareholders: n/a
No. of Employees: 3,851
Sector Healthcare
Industry Pharmaceuticals
Index Hang Seng Composite , Hang Seng Composite LargeCap & MidCap , Hang Seng Composite MidCap , Hang Seng Composite Mid & SmallCap ,
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 9,465,682,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
460 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 460
Upcoming Events for 460
Frequently Asked Questions for Sihuan Pharmaceutical Holdings
What is the Sihuan Pharmaceutical Holdings share price?

As of 3:59am, shares in Sihuan Pharmaceutical Holdings are trading at HK$0.9, giving the company a market capitalisation of £822.9m. This share price information is delayed by 15 minutes.

How has the Sihuan Pharmaceutical Holdings share price performed this year?

Shares in Sihuan Pharmaceutical Holdings are currently trading at HK$0.9 and the price has moved by 15.75% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sihuan Pharmaceutical Holdings price has moved by 3.55% over the past year.

What are the analyst and broker recommendations for Sihuan Pharmaceutical Holdings?

Of the analysts with advisory recommendations for Sihuan Pharmaceutical Holdings, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Sihuan Pharmaceutical Holdings is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Sihuan Pharmaceutical Holdings next release its financial results?

Sihuan Pharmaceutical Holdings is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Sihuan Pharmaceutical Holdings dividend yield?

The Sihuan Pharmaceutical Holdings dividend yield is 1.77% based on the trailing twelve month period.

Does Sihuan Pharmaceutical Holdings pay a dividend?

Last year, Sihuan Pharmaceutical Holdings paid a total dividend of 0.01, and it currently has a trailing dividend yield of 1.77%. Looking ahead, Sihuan Pharmaceutical Holdings has not announced an ex-dividend date yet.

When does Sihuan Pharmaceutical Holdings next pay dividends?

Sihuan Pharmaceutical Holdings has yet to annouce their ex-dividend date. The historic dividend yield on Sihuan Pharmaceutical Holdings shares is currently 1.77%.

How do I buy Sihuan Pharmaceutical Holdings shares?

To buy shares in Sihuan Pharmaceutical Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Sihuan Pharmaceutical Holdings?

Shares in Sihuan Pharmaceutical Holdings are currently trading at HK$0.9, giving the company a market capitalisation of £822.9m.

Where are Sihuan Pharmaceutical Holdings shares listed? Where are Sihuan Pharmaceutical Holdings shares listed?

Here are the trading details for Sihuan Pharmaceutical Holdings:

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 460
What kind of share is Sihuan Pharmaceutical Holdings?

Based on an overall assessment of its quality, value and momentum, Sihuan Pharmaceutical Holdings is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Sihuan Pharmaceutical Holdings share price forecast 2020?

Shares in Sihuan Pharmaceutical Holdings are currently priced at HK$0.9. At that level they are trading at 9.78% discount to the analyst consensus target price of 0.00.

Analysts covering Sihuan Pharmaceutical Holdings currently have a consensus Earnings Per Share (EPS) forecast of 0.076 for the next financial year.

How can I tell whether the Sihuan Pharmaceutical Holdings share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sihuan Pharmaceutical Holdings. Over the past six months, the relative strength of its shares against the market has been 7.09%. At the current price of HK$0.9, shares in Sihuan Pharmaceutical Holdings are trading at 16.98% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Sihuan Pharmaceutical Holdings PE Ratio?

The Sihuan Pharmaceutical Holdings PE ratio based on its reported earnings over the past 12 months is 41.63. The shares are currently trading at HK$0.9.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Sihuan Pharmaceutical Holdings?

Sihuan Pharmaceutical Holdings's management team is headed by:

Fengsheng Che - CHM
Weicheng Guo - CEO
Jionglong Zhang - CIN
Yiau Chong Choi - CFO
Wah Kwong Tsang - NID
Ming Wai Mok - SEC
Xun Zhu - NID
Jin Ha Kim - NED
Yanling Chen - EDR
Patrick Sun - NID
Who are the major shareholders of Sihuan Pharmaceutical Holdings?

Here are the top five shareholders of Sihuan Pharmaceutical Holdings based on the size of their shareholding:

Proper Process International Ltd. Corporation
Percentage owned: 30.45% (2.88bn shares)
Successmax Global Holdings Ltd. Corporation
Percentage owned: 13.34% (1.26bn shares)
Network Victory Ltd Corporation
Percentage owned: 5.26% (497.4m shares)
Victory Faith International Ltd. Corporation
Percentage owned: 3.99% (377.3m shares)
Guo (Weicheng) Individual Investor
Percentage owned: 3.48% (329.7m shares)
Similar to 460
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.